The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics
Abstract
Based on histopathology and molecular genetics, ovarian carcinomas are divided into five main types: high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%), and low-grade serous (<5%) carcinomas. These tumors, which account for over 95% of cases, represent distinct diseases with different prognoses and treatments. TP53 mutations are identified in almost all (96%) high-grade serous carcinomas (HGSCs). Early p53 loss followed by BRCA loss leads to deficiency in homologous recombination (DHR) repair, which in turn triggers chromosomal instability and widespread somatic copy number changes. An undetermined number of cases of HGSCs originate in the tubal fimbria; however, an origin from the ovarian surface epithelium cannot be totally excluded. Low-grade serous carcinomas (LGSCs) most likely represent progression of SBTs. BRAF or KRAS mutations occur in one-third to one-half of cases. Mucinous carcinomas (MCs) typically show benign-appearing, borderline, non-invasive and invasive components indicating tumor progression. KRAS mutations occur in 43.6% of cases and overexpression/amplification of HER2 in 18.8%. Endometrioid and clear cell carcinomas (EC and CCC) originate from ovarian endometriosis. Compared with their uterine counterparts, ECs have a similar frequency of β-catenin abnormalities but lower rate of microsatellite instability (MI) and PTEN alterations. ARID1A mutations occur in both ECs (30%) and CCCs (50%) and may be encountered in adjacent endometriosis. CCCs carry inactivating PTEN mutations and activating mutations in PIK3CA in 8% and 33% of cases, respectively. This review summarizes recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinomas and are also relevant to patient management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364
Self-citationHEINTZ, A., ODICINO, F., MAISONNEUVE, P., QUINN, M., BENEDET, J., CREASMAN, W., NGAN, H., PECORELLI, S., & BELLER, U. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60033-7 · Cited by 1,277
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Suzuki, M., Sato, I., & Taguchi, K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2584::aid-cncr22>3.0.co;2-5 · Cited by 795
Piek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Grading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670
Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament
Scully, R. E., Young, R. H., & Clement, P. B. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199907000-00019 · Cited by 617
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D., & Jacks, T. (2005) · Nature Medicine · doi:10.1038/nm1173 · Cited by 604
Prat, J. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1203-5 · Cited by 602
Self-citationPerets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Sato, N., Tsunoda, H., Nishida, M., Morishita, Y., Takimoto, Y., Kubo, T., & Noguchi, M. (2000) · PubMed · doi:10.11501/3187985 · Cited by 448
The genesis and evolution of high-grade serous ovarian cancer
Bowtell, D. D. L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2946 · Cited by 445
Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study
Falconer, H., Yin, L., Gronberg, H., & Altman, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju410 · Cited by 436
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Przybycin, C. G., Kurman, R. J., Ronnett, B. M., Shih, I.-M., & Vang, R. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ef7b16 · Cited by 410
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas.
Palacios, J., & Gamallo, C. (1998) · PubMed · Cited by 407
Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Konecny, G. E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K. R., Dering, J., Ginther, C., Chen, H.-W., Dowdy, S., Cliby, W., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju249 · Cited by 398
Powell, C. B., Kenley, E., Chen, L.-M., Crawford, B., McLennan, J., Zaloudek, C., Komaromy, M., Beattie, M., & Ziegler, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.109 · Cited by 372
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Lee, K. R. C. K., & Scully, R. E. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200011000-00001 · Cited by 343
Longacre, T. A., McKenney, J. K., Tazelaar, H. D., Kempson, R. L., & Hendrickson, M. R. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000164030.82810.db · Cited by 323
Chandler, R. L., Damrauer, J. S., Raab, J. R., Schisler, J. C., Wilkerson, M. D., Didion, J. P., Starmer, J., Serber, D., Yee, D., Xiong, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7118 · Cited by 323
Folkins, A. K., Jarboe, E. A., Saleemuddin, A., Lee, Y., Callahan, M. J., Drapkin, R., Garber, J. E., Muto, M. G., Tworoger, S., & Crum, C. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.012 · Cited by 293
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
McAlpine, J. N., Hanley, G. E., Woo, M. M. M., Tone, A. A., Rozenberg, N., Swenerton, K. D., Gilks, C. B., Finlayson, S. J., Huntsman, D. G., & Miller, D. M. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.01.003 · Cited by 286
Serous Borderline Tumors of the Ovary
Prat, J., & Nictolis, M. D. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200209000-00002 · Cited by 283
Self-citationSerous Carcinogenesis in the Fallopian Tube: A Descriptive Classification
Jarboe, E., Folkins, A., Nucci, M. R., Kindelberger, D., Drapkin, R., Miron, A., Lee, Y., & Crum, C. P. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31814b191f · Cited by 273
Histologic Transformation of Benign Endometriosis to Early Epithelial Ovarian Cancer
Sainz de la Cuesta, R., Eichhorn, J. H., Rice, L. W., Fuller, Jr., Nikrui, N., & Goff, B. A. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0032 · Cited by 272
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262
Schultheis, A. M., Ng, C. K. Y., De Filippo, M. R., Piscuoglio, S., Macedo, G. S., Gatius, S., Perez Mies, B., Soslow, R. A., Lim, R. S., Viale, A., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv427 · Cited by 262
Ovarian carcinoma pathology and genetics: recent advances
Gilks, C. B., & Prat, J. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.04.017 · Cited by 249
Self-citationMutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok, S. C., Bell, D. A., KNAPP, R. C., Fishbaugh, P. M., Welch, W. R., Muto, M. G., Berkowitz, R. S., & Tsao, S. (1993) · PubMed · Cited by 237
Köbel, M., Kalloger, S. E., Carrick, J., Huntsman, D., Asad, H., Oliva, E., Ewanowich, C. A., Soslow, R. A., & Gilks, C. B. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181788546 · Cited by 231
Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality
Anglesio, M. S., Wang, Y. K., Maassen, M., Horlings, H. M., Bashashati, A., Senz, J., Mackenzie, R., Grewal, D. S., Li-Chang, H., Karnezis, A. N., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv428 · Cited by 229
Kato, N., Sasou, S.-I., & Motoyama, T. (2006) · Modern Pathology · doi:10.1038/modpathol.3800492 · Cited by 226
Ducie, J., Dao, F., Considine, M., Olvera, N., Shaw, P. A., Kurman, R. J., Shih, I.-M., Soslow, R. A., Cope, L., & Levine, D. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01217-9 · Cited by 224
Grisham, R. N., Iyer, G., Garg, K., DeLair, D., Hyman, D. M., Zhou, Q., Iasonos, A., Berger, M. F., Dao, F., Spriggs, D. R., et al. (2013) · Cancer · doi:10.1002/cncr.27782 · Cited by 221
BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
Wong, K.-K., Tsang, Y. T. M., Deavers, M. T., Mok, S. C., Zu, Z., Sun, C., Malpica, A., Wolf, J. K., Lu, K. H., & Gershenson, D. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100212 · Cited by 220
Low‐grade serous carcinomas of the ovary contain very few point mutations
Jones, S., Wang, T., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3967 · Cited by 218
Rodríguez, I. M., & Prat, J. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200202000-00001 · Cited by 218
Self-citationHelland, Å., Anglesio, M. S., George, J., Cowin, P. A., Johnstone, C. N., House, C. M., Sheppard, K. E., Etemadmoghadam, D., Melnyk, N., Rustgi, A. K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018064 · Cited by 215
Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage.
Jiang, X., Morland, S. J., Hitchcock, A., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 207
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
Anglesio, M. S., Kommoss, S., Tolcher, M. C., Clarke, B., Galletta, L., Porter, H., Damaraju, S., Fereday, S., Winterhoff, B. J., Kalloger, S. E., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4088 · Cited by 198
Catasús, L., Bussaglia, E., Rodrı́guez, I., Gallardo, A., Pons, C., Irving, J. A., & Prat, J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.07.019 · Cited by 181
Self-citationKennedy, A. W., & Hart, W. R. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960715)78:2<278::aid-cncr14>3.0.co;2-t · Cited by 175
Ronnett, B. M., Yemelyanova, A. V., Vang, R., Gilks, C. B., Miller, D., Gravitt, P. E., & Kurman, R. J. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181758831 · Cited by 173
Mackenzie, R., Kommoss, S., Winterhoff, B. J. N., Kipp, B. R., García, J. J., Voss, J. S., Halling, K. C., Karnezis, A. N., Senz, J., Yang, W., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1421-8 · Cited by 172
Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers
Chan, W.-Y., Cheung, K.-K., Schorge, J. O., Huang, L.-W., Welch, W. R., Bell, D. A., Berkowitz, R. S., & Mok, S. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64744-x · Cited by 171
Vang, R., Levine, D. A., Soslow, R. A., Zaloudek, C., Shih, I.-M., & Kurman, R. J. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000207 · Cited by 170
Dehari, R., Kurman, R. J., Logani, S., & Shih, I. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31802cbbe9 · Cited by 168
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube
Chen, E. Y., Mehra, K., Mehrad, M., Ning, G., Miron, A., Mutter, G. L., Monte, N., Quade, B. J., McKeon, F. D., Yassin, Y., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2739 · Cited by 161
Kuhn, E., Meeker, A. K., Wang, T., Sehdev, A. E. S., Kurman, R. J., & Shih, I. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181dcede7 · Cited by 154
Yamamoto, S., Tsuda, H., Takano, M., Iwaya, K., Tamai, S., & Matsubara, O. (2011) · The Journal of Pathology · doi:10.1002/path.2940 · Cited by 152
Veras, E. F. T., Mao, T., Ayhan, A., Ueda, S. M., Lai, H. C., Hayran, M., Shih, I., & Kurman, R. J. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819c4271 · Cited by 151
Frequency of BRCA1 Dysfunction in Ovarian Cancer
Geisler, J. P. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.1.61 · Cited by 141
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Willner, J. B., Wurz, K., Allison, K. H., Galic, V., Garcia, R. L., Goff, B. A., & Swisher, E. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.007 · Cited by 135
Ovarian clear cell adenocarcinoma: a continuing enigma: Table 1
Tan, D. S. P., & Kaye, S. B. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.040030 · Cited by 134
Catasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2007) · Modern Pathology · doi:10.1038/modpathol.3800992 · Cited by 126
Self-citationRoles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis
Guan, B., Rahmanto, Y. S., Wu, R., Wang, Y., Wang, Z., Wang, T., & Shih, I. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju146 · Cited by 125
Irving, J. A., Catasús, L., Gallardo, A., Bussaglia, E., Romero, M., Matías‐Guiu, X., & Prat, J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.005 · Cited by 124
Self-citationIncidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases
Gilks, C. B., Irving, J., Köbel, M., Lee, C., Singh, N., Wilkinson, N. S., & McCluggage, W. G. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000353 · Cited by 123
Cuatrecasas, M., Catasús, L., Palacios, J., & Prat, J. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318188b84c · Cited by 120
Self-citationTsang, Y. T. M., Deavers, M. T., Sun, C. C., Kwan, S., Kuo, E., Malpica, A. L., Mok, S. C., Gershenson, D. M., & Wong, K. (2013) · The Journal of Pathology · doi:10.1002/path.4252 · Cited by 119
Komiyama, S., Aoki, D., Tominaga, E., Susumu, N., Udagawa, Y., & Nozawa, S. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5284 · Cited by 119
Emmanuel, C., Chiew, Y.-E., George, J., Etemadmoghadam, D., Anglesio, M. S., Sharma, R. N., Russell, P., Kennedy, C. J., Fereday, S., Hung, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1292 · Cited by 118
Hoskins, P. J., Le, N., Gilks, B., Tinker, A., Santos, J., Wong, F., & Swenerton, K. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1646 · Cited by 117
Howitt, B. E., Strickland, K. C., Sholl, L. M., Rodig, S. J., Ritterhouse, L. L., Chowdhury, D., D’Andrea, A. D., Matulonis, U. A., & Konstantinopoulos, P. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1277308 · Cited by 116
Evidence for a Dualistic Model of High-grade Serous Carcinoma
Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N. S., Crum, C. P., & Meserve, E. E. K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000369 · Cited by 111
Tang, S., Onuma, K., Deb, P., Wang, E., Lytwyn, A., Sur, M., & Daya, D. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31822ea955 · Cited by 107
Rabban, J. T., Garg, K., Crawford, B., Chen, L.-M., & Zaloudek, C. J. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000199 · Cited by 104
Caduff, R. F., Svoboda-Newman, S. M., Ferguson, A. W., Johnston, C. M., & Frank, T. S. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199903000-00012 · Cited by 102
VANG, R. S., Gown, A. M., Barry, T. S., Wheeler, D. T., & Ronnett, B. M. (2005) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000177125.31046.fd · Cited by 100
George, J., Alsop, K., Etemadmoghadam, D., Hondow, H., Mikeska, T., Dobrovic, A., DeFazio, A., Chenevix‐Trench, G., Smyth, G. K., Levine, D. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0066 · Cited by 98
Rambau, P., McIntyre, J. B., Taylor, J. L., Lee, S., Ogilvie, T., Sienko, A. E., Morris, D. G., Duggan, M. A., McCluggage, W. G., & Köbel, M. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000812 · Cited by 93
Köbel, M., Kalloger, S. E., Lee, S., Duggan, M. A., Kelemen, L. E., Prentice, L., Kalli, K. R., Fridley, B. L., Visscher, D. W., Keeney, G. L., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0391 · Cited by 90
The Ovary Is an Alternative Site of Origin for High-Grade Serous Ovarian Cancer in Mice
Kim, J., Coffey, D. M., Ma, L., & Matzuk, M. M. (2015) · Endocrinology · doi:10.1210/en.2014-1977 · Cited by 85
Morrison, J. C., Blanco, L. Z., Vang, R., & Ronnett, B. M. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000352 · Cited by 84
Epigenetic determinants of ovarian clear cell carcinoma biology
Yamaguchi, K. D., Huang, Z., Matsumura, N., Mandai, M., Okamoto, T., Baba, T., Konishi, I., Berchuck, A., & Murphy, S. K. (2013) · International Journal of Cancer · doi:10.1002/ijc.28701 · Cited by 79
Seromucinous Tumors of the Ovary. What’s in a Name?
Kurman, R. J., & Shih, I. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000266 · Cited by 79
Ali, R. H., Seidman, J. D., Luk, M., Kalloger, S. E., & Gilks, C. B. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31824d7445 · Cited by 77
Shvartsman, H. S., Sun, C. C., Bodurka, D. C., Mahajan, V., Crispens, M. A., Lu, K. H., Deavers, M. T., Malpica, A. L., Silva, E. G., & Gershenson, D. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.030 · Cited by 73
Uzan, C., Nikpayam, M., Ribassin-Majed, L., Gouy, S., Bendifallah, S., Cortez, A., Rey, A., Morice, P., Daraï, É., & Morice, P. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu139 · Cited by 73
Crum, C. P., Herfs, M. F., Ning, G., Bijron, J. G., Howitt, B. E., Jimenez, C. A., Hanamornroongruang, S., McKeon, F., & Xian, W. (2013) · The Journal of Pathology · doi:10.1002/path.4263 · Cited by 71
Zeppernick, F. A., Ardighieri, L., Hannibal, C. G., VANG, R. S., Junge, J., Kjær, S. K., Zhang, R., Kurman, R. J., & Shih, I. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000313 · Cited by 69
Yamamoto, S., Tsuda, H., Takano, M., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2386 · Cited by 68
The Role of Hepatocyte Nuclear Factor-1A in the Pathogenesis of Clear Cell Carcinoma of the Ovary
Kobayashi, H., Yamada, Y., Kanayama, S., Furukawa, N., 野口, 武., Haruta, S., Yoshida, S., Sakata, M., Sado, T., & Oi, H. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a19eca · Cited by 68
High Rates of Occult Fallopian Tube Cancer Diagnosed at Prophylactic Bilateral Salpingo-Oophorectomy
Hirst, J. E., Gard, G. B., McIlroy, K., Nevell, D. F., & Field, M. J. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a1b5dc · Cited by 67
Baek, S.-J., Park, J., Kim, D., Kim, J.-H., Kim, Y., Kim, Y., & Nam, J. (2008) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2008.19.4.223 · Cited by 65
Yamamoto, S., Tsuda, H., Yoshikawa, T., Kudoh, K., Kita, T., Furuya, K., Tamai, S., & Matsubara, O. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000249449.13466.3c · Cited by 63
Micropapillary pattern in serous borderline ovarian tumors: Does it matter?
Park, J., Kim, D., Kim, J.-H., Kim, Y., Kim, K.-R., Kim, Y., & Nam, J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.008 · Cited by 62
Hereditary gynaecological malignancies: advances in screening and treatment
Folkins, A. K., & Longacre, T. A. (2012) · Histopathology · doi:10.1111/his.12028 · Cited by 61
Clear cell carcinomas of the ovary and kidney: clarity through genomics
Ji, J. X. Y., Wang, Y. K., Cochrane, D. R., & Huntsman, D. D. (2018) · The Journal of Pathology · doi:10.1002/path.5037 · Cited by 55
Post, M. D. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.113 · Cited by 41
Expression of ?-glutamyl cysteine synthetase in nonsmall cell lung carcinoma
Soini, Y., T�rm�nen-N�p�nkangas, U., J�rvinen, K., Kaarteenaho–Wiik, R., P��kk�, P., & Kinnula, V. L. (2001) · Cancer · doi:10.1002/1097-0142(20011201)92:11<2829::aid-cncr10094>3.0.co;2-3 · Cited by 40
Espinosa, Í., Catasús, L., Canet, B., D′Angelo, E., Muñoz, J., & Prat, J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.12 · Cited by 33
Self-citationHistopathologic features of ovarian borderline tumors are not predictive of clinical outcome
Avril, S., Hahn, E., Specht, K., Hauptmann, S., Höß, C., Kiechle, M. B., Höfler, H., & Schmalfeldt, B. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.08.027 · Cited by 30
Role of HNF1β in the differential diagnosis of yolk sac tumor from other germ cell tumors
Rougemont, A., & Tille, J. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.04.025 · Cited by 30
Karnezis, A. N., Aysal, A., Zaloudek, C. J., & Rabban, J. T. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826a5399 · Cited by 20
Cited by
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022: Featured Updates to the NCCN Guidelines
Armstrong, D. K., Alvarez, R. D., Backes, F. J., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Chitiyo, V. C., Cristea, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0047 · Cited by 401
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Soong, T. R., Howitt, B. E., Horowitz, N., Nucci, M. R., & Crum, C. P. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.033 · Cited by 110
Pecorino, B., Laganà, A. S., Chiantera, V., Ferrara, M., Di Stefano, A. B., Di Donna, M. C., Sorrentino, F., Nappi, L., Mikuš, M., & Scollo, P. (2022) · Medicina · doi:10.3390/medicina58121706 · Cited by 12
Metadata
- Authors
- Prat, J., D'Angelo, E., & Espinosa, I.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 80
- Pages
- 11-27
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W2810781719
- Cited by
- 275
- References
- 116
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.